Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells

Molecular Cancer Therapeutics

Volumn 9, Issue 8, 2010, Pages 2276-2286

  Chang, Chien Hsing ^a,b   Gupta, Pankaj ^a   Michel, Rosana ^a   Loo, Meiyu ^b   Wang, Yang ^a   Cardillo, Thomas M ^a   Goldenberg, David M ^c  

^a IMMUNOMEDICS INC   (United States)

^b IBC Pharmaceuticals Inc   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOTOXIN; MILATUZUMAB; MONOCLONAL ANTIBODY; RANPIRNASE; RIBONUCLEASE; TRANSFER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PANCREAS CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; TOXICITY TESTING; TUMOR GROWTH; UTERINE CERVIX CANCER;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANURA; CELL ADHESION MOLECULES; CELL DEATH; CELL LINE, TUMOR; ENDOCYTOSIS; EPITHELIUM; HUMANS; MAXIMUM TOLERATED DOSE; MICE; PROTEIN BIOSYNTHESIS; RIBONUCLEASES; SUBCELLULAR FRACTIONS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955480479     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0338     Document Type: Article

References (50)

1. Lee I. Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumor physical parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. Exp Opin Biol Ther 2008;8:813-27.
2. Ardelt W, Shogen K, Darzynkiewicz Z. Onconase and Amphinase, the antitumor ribonucleases from Rana pipiens oocytes. Curr Pharm Biotechnol 2008;9:215-25. (Pubitemid 352024698)
3. Lee JT, Raines RT. Ribonucleases as novel chemotherapeutics. The ranpirnase example. Biodrugs 2008;22:53-8.
4. Costanzi J, Sidransky D, Navon A, Goldsweig H. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinial and clinical data for ranpirnase. Cancer Invest 2005;23:643-50.
5. Mutti L, Gaudino G. The therapeutic potential of the novel ribonuclease ranpirnase (Onconase) in the treatment of malignant mesothelioma. Oncol Rev 2008;2:61-5.
6. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unrsectable malignant mesothelioma. J Clin Oncol 2002;20:274-81.
7. Mikulski SM, Grossman AM, Carter PW, Shogen K, Costanzi JJ. Phase I human clinical trial of onconase (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors. Int J Oncol 1993;3:57-64.
8. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 2001;97:528-35.
9. ChangCH, Sapra P, VanamaSS, HansenHJ,Horak ID,GoldenbergDM. Effective therapy of human lymphoma xenografts with a novel recombinant rebonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005;106:4308-14.
10. Stein R, Qu Z, Cardillo T, et al. Anti-proliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004;104:3705-11.
11. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology 2002;105:9-19.
12. Liao Y-D, Wang S-S, Leu Y-J, et al. The structural integrity exerted by N-terminal pyroglutamate is crucial for the cytotoxicity of frog ribonuclease from Rana pipiens. Nucleic Acids Res 2003;31:5247-55.
13. Fornaro M, Dell'Arciprete R, Stella M, et al. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer 1995;62:610-8.
14. Sewedy TE, Fornaro M, Alberti S. Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer 1998;75:324-30. (Pubitemid 28100077)
15. Ripani E, Sacchetti A, Corda D, Alberti S. Human TROP-2 is a tumorassociated calcium signal transducer. Int J Cancer 1998;76:671-6.
16. Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Identification of TROP-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008;7:280-5.
17. Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009; 1796:309-14.
18. Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, Geradts J. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res 2005;11:4357-64.
19. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006;12:3057-63. (Pubitemid 43837351)
20. Fang YJ, Lu ZH, Wang GQ, et al. Elevated expression of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver matastasis of colon cancer. Int J Colorectal Dis 2009;24:875-84.
21. Fong D, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Modern Pathol 2008;21:186-91.
22. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A 2008; 105:20882-7.
23. Stein R, Chen S, Sharkey RM, Goldenberg DM. Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: specificity and tumor targeting. Cancer Res 1990;50: 1330-6. (Pubitemid 20084030)
24. Stein R, Basu A, Chen S, Shih LB, Goldenberg DM. Specificity and properties of Mab RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer 1993;55: 938-46.
25. Stein R, Basu A, Goldenberg DM, Looyd KO, Mattes MJ. Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7. Int J Cancer 1994;8:98-102. (Pubitemid 24188968)
26. Stein R, Blumenthal R, Sharkey RM, Goldenberg DM. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab′)2 in nude mice bearing human tumor xenografts. Cancer 1994;73:816-23. (Pubitemid 24046636)
27. Shih LB, Xuan H, Aninipot R, Stein R, Goldenberg DM. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Cancer Res 1995;55:5857-63s.
28. 131I. J Nucl Med 2001;42:967-74.
29. Qu Z, Griffiths GL, Wegener WA, et al. Development of humanized antibodies as cancer therapeutics. Methods 2005;36:84-95.
30. Vanama SS, Sapra P, Hansen HJ, Horak ID, Goldenberg DM, Chang C-H. Construction and characterization of two recombinant immunotoxins consisting of glycosylated and non-glycosylated ranpirnase fused to an internalizing anti-CD74 humanized IgG4 antibody [Abstract]. Cancer Biother Radiopharm 2004;19:514.
31. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006;8:E532-51.
32. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65.
33. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatments of cancer. Annu Rev Med 2007;58:221-37.
34. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009;23:1-13.
35. De Lorenzo C, Nigro A, Piccoli R, D'Alessio G. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-expressing cells. FEBS Lett 2002;516:208-12. (Pubitemid 34311963)
36. De Lorenzo C, Arciello A, Cozzolino R, et al. A fully human antitumor immunoRNase selective for ErbB2-positive carcinomas. Cancer Res 2004;64:4870-4.
37. Schirrmann T, Krauss J, Arndt MAE, Rybak SM, Dübel S. Targeted therapeutic RNases (ImmunoRNases). Exp Opin Biol Ther 2009;9: 79-95.
38. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8.
39. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL-22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241-7.
40. Pai LH, FitzGerald DJ, Tepper M, Schacter B, Spitalny G, Pastan I. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 1990;50:7750-3.
41. Siegall CB, Haggerty HG, Warner GL, et al. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLAIg enhances antitumor efficacy. J Immunol 1997;159: 5168-73.
42. Frankel AE. Reducing the immune response to immunotoxin. Clin Cancer Res 2004;10:13-5.
43. Iordanov MS, Ryabinina OP, Wong J, et al. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 2000;60:1983-94. (Pubitemid 30207661)
44. Rodriguez M, Torrent G, Bosch M, et al. Intracellular pathway of onconase that enables its delivery to the cytosol. J Cell Sci 2007; 120:1405-11.
45. Haigis MC, Raines RT. Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway. J Cell Sci 2003;116: 313-24.
46. Wu Y, Saxena SK, Ardelt W, et al. A study of the intracellular routing of cytotoxic ribonucleases. J Biol Chem 1995;270:17476-81.
47. Leich F, Stöhr N, Bietz A, Ulbrich-Hofmann R, Arnold U. Endocytic internalization as a crucial factor for the cytotoxicity of ribonucleases. J Biol Chem 2007;282:27640-6. (Pubitemid 47529500)
48. Bracale A, Spalletti-Cernia D, Mastronicola M, et al. Essential stations in the intracellular pathway of cytotoxic bovine seminal ribonuclease. Biochem J 2002;362:553-60.
49. De Lorenzo C, Di Malta C, Cali G, Troise F, Nitsch L, D'Slessio G. Intracelluar route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. FEBS Lett 2007;581: 296-300. (Pubitemid 46096473)
50. Menzel C, Schirmann T, Konthur Z, Jostock T, Dübel S. Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood 2008;111:3830-7.